

2021 - 2022 ACTRIMS Didactic Series

Disclosure Information

As a provider dedicated to independent education and accredited by the ACCME, IPMA must ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. All individuals with potential to influence the content of this program have disclosed all financial relationships that have occurred in the past 24 months with ineligible companies. The disclosures have been reviewed according to policy and these declarations are listed below. All individuals with potential conflicts have been contacted as needed by IPMA staff, and issues of conflict have been discussed, managed, and mitigated.

Individual	Role	Disclosure
Lilyana Amezcua, MD, MS	Faculty	Advisory Board & Consultant: EMD Serono; Advisory
		Board & Research: Genentech; Advisory Board: AbbVie,
		Novartis; Consultant: Alexion, Biogen
Laura Baldassari	Faculty	Disclosure not required as topic was non-clinical
Brenda Banwell, MD	Faculty	Consultant: Novartis, UCB, Roche, Sanofi
Jeffrey Bennett, MD, PhD	Faculty	Consultant: Alexion Pharmaceuticals, Inc., Antigenomycs,
		Genentech/Roche, Horizon Therapeutics, Mitsubishi-
		Tanabe, Reistone-Bio; Data Safety and Monitoring
		Board: Clene Nanomedicine Consultant and Research:
		Novartis Pharma Ag; Research: Mallinckrodt
Riley Bove, MD	Faculty	Advisory Board, Consultant & Research: Novartis
		Advisory Board & Research: Biogen Research: EMD
		Serono Advisory Board: Alexion, TG Therapeutics
		Advisory Board & Consultant: Genzyme Sanofi
Kim Burchiel, MD	Faculty	No relevant relationships with ineligible companies to
		disclose
Leonard Calabrese, DO	Faculty	No relevant relationships with ineligible companies to
		disclose
Stacey Clardy, MD, PhD	Faculty	Research: Alexion, Viela Bio/Horizon,
		Alexion/AstraZeneca; Advisory Board: Alexion,
		VielaBio/Horizon, Genentech/Roche
Jeffrey Cohen, MD	Faculty	Consultant: Biogen, Bristol-Myers Squibb, Convelo,
		Genentech, Janssen, NervGen, Novartis, PSI
John Corboy, MD	Planning	No relevant relationships with ineligible companies to
		disclose
Josep Dalmau, MD, PhD	Faculty	Research: Euroimmune, antibody testing, SAGE,
		allosteric modulator of NMDAR
Nina S. Davis, MD	Faculty	No relevant relationships with ineligible companies to
		disclose
Kathryn Fitzgerald	Faculty	No relevant relationships with ineligible companies to
		disclose
Eoin Flanagan, MBBCh	Faculty	Advisory Board: Alexion, Genentech, Horizon
		Therapeutics; Research: Horizon Therapeutics
Robert Fox, MD	Faculty	Consultant: AB Science, Actelion, Biogen, Celgene, EMD
		Serono, Genentech, Immunic, Novartis, Sanofi, and TG
		Therapeutics

Jeffrey Gelfand, MD	Faculty	Consultant: Biogen, Advisory Board, Consultant & Research: Genentech/Roche Research: Vigil Neurosciences
Jordan Haag	Program Planning	No relevant relationships with ineligible companies to disclose
Sarah Hopkins, MD	Planning	No relevant relationships with ineligible companies to disclose
Le Hua, MD	Program Planning	Consultant: Alexion, Genentech, Greenwich Biosciences, Horizon, Novartis Advisory Board & Speakers Bureau: Bristol Myers Squibb, Genzyme Advisory Board & Consultant: EMD Serono Research: Biogen
Mirhir Kakara, MD	Planning	No relevant relationships with ineligible companies to disclose
Annette Langer-Gould	Faculty	Disclosure not requires as topic was non-clinical
Erin Longbrake, MD, PhD	Program Planning	Advisory Board & Research: Genentech Advisory Board: Alexion, Biogen, Genzyme
Christopher Luzzio, MD	Content Review	No relevant relationships with ineligible companies to disclose
Wendy Macklin, PhD	Faculty	No relevant relationships with ineligible companies to disclose
Derck McFaul, DO	Faculty	No relevant relationships with ineligible companies to disclose
Andrew McKeon, MD	Faculty	Research: Euroimmun AG, Alexion
Heidi Ness	Program Planning	No relevant relationships with ineligible companies to disclose
Bardia Nourbakhsh, MD	Faculty	Research: Genentech
Ahmed Obeidat, MD	Planner	Advisory Board, Consultant & Speakers Bureau: Alexion
Jennifer Orthmann Murphy, MD, PhD	Faculty	Research: Vigil Neurosciences, Inc.
John Peters, MD	Planner	No relevant relationships with ineligible companies to disclose
Michael Racke	Faculty	Disclosure not required as topic was non-clinical
John Ratchford	Faculty	Disclosure not required as topic was non-clinical
Bruce Trapp, MD	Faculty	No relevant relationships with ineligible companies to disclose
Mitch Wallin	Faculty	No relevant relationships with ineligible companies to disclose
Vijayshree Yadav, MD	Planner	No relevant relationships with ineligible companies to disclose
Emily Viles-Monari	Program Planning	No relevant relationships with ineligible companies to disclose